Literature DB >> 2855108

The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI 67. Application of the method to paraffin embedded specimens.

D K Böker1, H J Stark.   

Abstract

60 intracranial tumors have been studied immunohistochemically to determine the proliferation rate by staining for the monoclonal antibody KI-67, which recognizes a nuclear antigen expressed by cells in proliferation. In gliomas a clear correlation of stained nuclei to the histologically determined degree of malignancy was found: slow growing astrocytomas and oligodendrogliomas had an average proliferation rate of 1%, more malignant forms of 7-10%. Glioblastomas were found to have a growth fraction of 15%. Metastases had an even higher rate of 20% proliferating cells. In meningiomas the proliferation rate was mainly about 1%, but in three cases it was between 5% and 7%. Whether this is indicative for a higher risk of tumor recurrence, remains to be correlated to the clinical course. Hemangiopericytomas had a proliferation rate of 9% and 16%, respectively, the latter recurring within four months. It may be concluded from the results of this study, that investigation of intracranial tumors with KI 67 may be of prognostic value and can possibly contribute to an individualized tumor therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2855108     DOI: 10.1007/bf01741421

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  22 in total

1.  The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology.

Authors:  P C Burger; T Shibata; P Kleihues
Journal:  Am J Surg Pathol       Date:  1986-09       Impact factor: 6.394

2.  The relationship between growth rate, labelling index and histological type of human solid tumours.

Authors:  E P Malaise; N Chavaudra; M Tubiana
Journal:  Eur J Cancer       Date:  1973-04       Impact factor: 9.162

3.  Cell kinetics of human gliomas.

Authors:  T Hoshino; M Barker; C B Wilson; E B Boldrey; D Fewer
Journal:  J Neurosurg       Date:  1972-07       Impact factor: 5.115

4.  The prediction of recurrence in meningiomas.

Authors:  M R Crompton; P C Gautier-Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-02       Impact factor: 10.154

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  Histologic factors of prognostic significance in the glioblastoma multiforme.

Authors:  P C Burger; R T Vollmer
Journal:  Cancer       Date:  1980-09-01       Impact factor: 6.860

7.  Cell kinetic analyses of human malignant brain tumors (gliomas).

Authors:  T Hoshino; C B Wilson
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

8.  The recurrence of intracranial meningiomas.

Authors:  S Melamed; A Sahar; A J Beller
Journal:  Neurochirurgia (Stuttg)       Date:  1979-03

9.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  A B Adegbite; M I Khan; K W Paine; L K Tan
Journal:  J Neurosurg       Date:  1983-01       Impact factor: 5.115

10.  In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.

Authors:  T Hoshino; T Nagashima; J A Murovic; C B Wilson; M S Edwards; P H Gutin; R L Davis; S J DeArmond
Journal:  J Neurosurg       Date:  1986-03       Impact factor: 5.115

View more
  7 in total

1.  Proliferating cell nuclear antigen expression in central nervous system neoplasms.

Authors:  A Allegranza; S Girlando; G L Arrigoni; S Veronese; F A Mauri; M Gambacorta; B Pollo; P Dalla Palma; M Barbareschi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 2.  The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.

Authors:  J F Reavey-Cantwell; R I Haroun; M Zahurak; R E Clatterbuck; R J Parker; R Mehta; J P Fruehauf; H Brem
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

3.  The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.

Authors:  R Schröder; K Bien; R Kott; I Meyers; R Vössing
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics.

Authors:  Paulo Henrique Aguiar; Ana Maria Tsanaclis; Oswaldo Inácio Tella; José Pindaro Plese
Journal:  Neurosurg Rev       Date:  2003-04-08       Impact factor: 3.042

5.  Immunohistochemical Analysis of the Cell Cycle-Associated Antigens Ki-67 and Retinoblastoma Protein in Parathyroid Carcinomas and Adenomas.

Authors:  Ricardo V. Lloyd; J. Aidan Carney; Jorge A. Ferreiro; Long Jin; Geoffrey B. Thompson; Jon A. Van Heerden; Clive S. Grant; Peter C. Wollan
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

6.  Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.

Authors:  E Karamitopoulou; E Perentes; I Diamantis; T Maraziotis
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

7.  Alteration of the Ki-67 Proliferative Index following Surgical Resection with or without Radiation Therapy of Intracranial Meningiomas.

Authors:  Amir H Faraji; Daniel A Tonetti; John C Flickinger; Johnathan A Engh
Journal:  Cureus       Date:  2017-11-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.